Mazdutide Multi-Cycle Dosing for Weight Loss and Metabolic Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing obesity treatments, such as GLP-1 single receptor agonists, fail to achieve significant weight loss in obese individuals with high BMIs and are associated with side effects, necessitating a more effective and safer dosing regimen for mazdutide, a dual GLP-1R and GCGR agonist.
Innovation Solution
A dosing regimen for mazdutide involving multiple dosing cycles with varying doses and frequencies over specific durations, including cycles of one, two, three, or four weekly administrations of 2.2 mg-3.5 mg doses, optimized for weight loss and safety.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If GLP-1 single receptor agonists are used for weight loss treatment, then some weight loss efficacy is achieved, but the weight loss effect is insufficient and side effects occur
Solution Approach 1:
The patent combines GLP-1R and GCGR dual agonism into a single molecule (mazdutide), merging the therapeutic effects of two separate receptors to achieve synergistic weight loss while maintaining tolerability. This is evidenced by the clinical trial data showing superior weight loss compared to GLP-1R agonist alone.
Solution Approach 2:
Mazdutide is designed as a composite peptide structure containing both GLP-1R agonist and GCGR agonist moieties, creating a single-molecule multi-receptor agonist that activates multiple metabolic pathways simultaneously for enhanced efficacy.
2Quantity of substance
If high dose mazdutide is administered to achieve maximum weight loss, then weight loss efficacy improves, but safety and tolerability may be compromised
Solution Approach 1:
The dosing regimen is segmented into multiple escalation phases (Phase 1: 2.2-2.8mg, Phase 2: 3.0-3.5mg, Phase 3: 4.0-4.5mg, Phase 4: 5.0-5.5mg), allowing gradual dose increase to identify the maximum tolerated dose while maintaining safety monitoring at each stage.
Solution Approach 2:
The dosing strategy employs dynamic dose adjustment based on individual patient response and tolerability, with the ability to escalate or de-escalate doses within each phase, rather than using a fixed high dose for all patients.
3Quantity of substance
If mazdutide dosing regimen is optimized for maximum efficacy, then weight loss and metabolic improvements are enhanced, but the complexity of dosing protocol increases
Solution Approach 1:
The dosing regimen follows a periodic structure with defined phases (4 phases of 4 weeks each, with optional extension), where dose escalation occurs at regular intervals, providing a systematic approach that balances efficacy optimization with protocol manageability.
Data Source
AI summary
The present invention belongs to the field of medicine, and specifically relates to a treatment method using mazdutide. The present invention provides a method for preventing or treating overweight and obesity, and a method for improving body weight in patients in need, the method comprising administering, to a patient in need, a prophylactically or therapeutically effective amount of a target compound in a dosage regimen comprising at least three dosing cycles. The present invention also provides a target compound, which is used for preventing or treating overweight or obesity in patients in need, wherein a prophylactically or therapeutically effective amount of the target compound is administered in at least three dosing cycles to a patient in need. The mazdutide dosage regimen provided has a remarkable weight reduction effect, noticeable weight reduction can be achieved with relatively low dosage in a relatively short amount of time, and blood pressure, blood lipid, and serum uric acid levels of a subject can simultaneously be improved.